Mycophenolate mofetil for myasthenia gravis - An analysis of efficacy, safety, and tolerability

被引：92

作者：

Meriggioli, MN

Ciafaloni, E

Al-Hayk, KA

Rowin, J

Tucker-Lipscomb, B

Massey, JM

Sanders, DB

机构：

[1] Rush Univ, Dept Neurol Sci, Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA

[2] Univ Rochester, Sch Med, Dept Neurol, Rochester, NY 14627 USA

[3] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA

来源：

NEUROLOGY | 2003年 / 61卷 / 10期

关键词：

D O I：

10.1212/01.WNL.0000094122.88929.0B

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America ( MGFA) postintervention status ( PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.

引用

页码：1438 / 1440

页数：3

共 11 条

[1] Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases [J].